Skip to main content

Embracing Direct-to-Consumer Advertising by Focusing on Stopping Medications



There are plenty of examples of direct-to-consumer advertising that the pharmaceutical industry use to lure new customers. Just like the Cancer Center ads we discussed in the last GeriPal post, these ads almost universally do this by making emotional appeals to the consumer, as well as focusing on the benefits rather than presenting any real discussion of risks.

What if someone used a similar concept, but instead of trying to get people to take a drug, they try to convince patients to stop one. That’s just what Cara Tannenbaum and colleagues did in a paper published in JAMA IM, albeit they called it direct-to-consumer patient education and empowerment.

The Study

In brief, the authors of this study conducted a cluster randomized trial in Quebec in which a total of 303 long-term users of benzodiazepine medication aged 65-95 years were recruited from 30 community pharmacies. These pharmacies were randomized to either a control arm or the educational intervention arm.

The educational intervention was an eight page booklet that was mailed to the patient (and can be downloaded here) describing the risks of benzodiazepine use and a stepwise tapering protocol. Like other direct-to-consumer advertising, they also include a patient testimonial "intended to augment self-efficacy."

What they found was striking. Complete cessation of benzodiazepine use in the 6 months following randomization was achieved in 40 of the 148 (27%) in the intervention arm compared to 7 of the 155 (5%) in the control arm. Even better, the number needed to treat for any discontinuation or dose reduction was 3.7 in an intention to treat analyses.

The Take Away

Health care professionals should embrace direct to consumer advertising as it isn't going away.  How?  Just imagine a world (or just the US and New Zealand as I think they are the only Western nations that allow direct-to-consumer advertising) where after every time a drug company markets a drug to consumers, especially a potentially habit forming drug like the ad below, these companies also have to pay for an intervention like this one that gets those very same people off of their drug when it is no longer indicated or inappropriately prescribed.  Now that would make me sleep more comfortably at night.



by: Eric Widera (@ewidera)

Comments

Popular posts from this blog

Dying without Dialysis

There is a terrific article in this weeks Journal of Pain and Symptom Management by Fliss Murtagh of King's College in London about the epidemiology of symptoms for patients with advanced renal failure who die without dialysis.  This study is important because while we know that patients with advanced renal failure have a limited life expectancy and the average age of initiation of hemodialysis is increasing, we know little about the alternatives to hemodialysis.  Specifically, we know nothing about symptoms affecting quality of life among patients who elect not to start dialysis (so called "conservative management" - is this the best label?).  This article provides a terrific counterpoint to the article in last years NEJM showing that nursing home residents who initiated hemodialysis tended to die and decline in function (see GeriPal write up here). 

The study authors followed patients with the most advanced form of chronic kidney disease (the new name for renal failu…

Language Matters: Podcast with Brian Block and Anna DeForest

One of our first GeriPal posts was titled "Rant on Terminology," by Patrice Villars, NP.  In the spirit of looking back over our first 10 years, here is the opening paragraph to that post:

News Headlines read: Sen. Edward Kennedy loses battle with cancer. Really, he lost? I thought he died from a malignant brain tumor, an “aggressive” brain tumor. The median survival is less than a year for people for his particular tumor. Kennedy was diagnosed in May of 2008. He lived over 15 months after diagnosis. What a loser. He must not have fought hard enough. Huh? I thought he spent most of his life battling for social and health care reform in America. In this week's GeriPal podcast we take a deeper dive into this issue of language and medicine.  We are joined by guests Anna DeForest, MD, MFA, a resident in Neurology at Yale, and Brian Block, MD, a pulmonary critical care fellow at UCSF.  

Anna recently published a paper in the NEJM describing her reaction to hearing terms like, &…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …